Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients

Highlights • Hepatitis B surface antigen (HBsAg) levels at hepatitis B e antigen (HBeAg) seroconversion may be an effective predictor of virological relapse. • The variation in HBsAg levels can help guide the timing of cessation of entecavir treatment. • Off-treatment virological relapse rates after...

Full description

Saved in:
Bibliographic Details
Published in:International journal of infectious diseases 2016-02, Vol.43 (C), p.43-48
Main Authors: Qiu, Yuan-wang, Huang, Li-hua, Yang, Wen-long, Wang, Zhen, Zhang, Bo, Li, Yi-guang, Su, Ting-ting, Zhou, Hong-yan, Xu, Wei, Wang, Xue-dong, Dai, Ya-ping, Gan, Jian-he
Format: Article
Language:English
Subjects:
Adult
Antiviral Agents - administration & dosage
Biomarkers - blood
China - epidemiology
Chronic hepatitis B
Entecavir
Female
Guanine - analogs & derivatives
Guanine - therapeutic use
Hepatitis B e Antigens - blood
Hepatitis B surface antigen
Hepatitis B Surface Antigens - blood
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - epidemiology
Hepatitis B, Chronic - immunology
Humans
Infectious Disease
Male
Middle Aged
Pulmonary/Respiratory
Recurrence
Relapse
Seroconversion - drug effects
Treatment Outcome
Viral Load - immunology
Withdrawal
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c521t-9e792a2dd46f98b2b8fa7172a662e4d03eb052505f55c90a736cf5b52ea853623
cites cdi_FETCH-LOGICAL-c521t-9e792a2dd46f98b2b8fa7172a662e4d03eb052505f55c90a736cf5b52ea853623
container_end_page 48
container_issue C
container_start_page 43
container_title International journal of infectious diseases
container_volume 43
creator Qiu, Yuan-wang
Huang, Li-hua
Yang, Wen-long
Wang, Zhen
Zhang, Bo
Li, Yi-guang
Su, Ting-ting
Zhou, Hong-yan
Xu, Wei
Wang, Xue-dong
Dai, Ya-ping
Gan, Jian-he
description Highlights • Hepatitis B surface antigen (HBsAg) levels at hepatitis B e antigen (HBeAg) seroconversion may be an effective predictor of virological relapse. • The variation in HBsAg levels can help guide the timing of cessation of entecavir treatment. • Off-treatment virological relapse rates after stopping entecavir treatment were assessed.
doi_str_mv 10.1016/j.ijid.2015.10.019
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7bb1970ad695427cb9636bdd4d9fa4e8</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1201971215002532</els_id><doaj_id>oai_doaj_org_article_7bb1970ad695427cb9636bdd4d9fa4e8</doaj_id><sourcerecordid>1765114372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c521t-9e792a2dd46f98b2b8fa7172a662e4d03eb052505f55c90a736cf5b52ea853623</originalsourceid><addsrcrecordid>eNp9Uk1v1TAQjBCIlsIf4IB85JKHP2I7lhASVEArVeIAnC3H2bw65MWp7TypP5D_hU1KQQhxsr07MyvvTFU9J3hHMBGvxp0bXb-jmPBc2GGiHlSnpJVtzTghD_M9t2olCT2pnsQ4YowbIdrH1QkVnDLB1Gn1_QIWk1xyEb1DcQ2DsYDMnNweZnSzltvgbEb4GZmErv9A_8ZFCN76-QghFtwSoHc2RXR0wU9-n_kTCjCZJWbOkCCgdA3IQoybsB8QzAmsyQSUAph0yG_k5n_Pqxcfc-0IqDQzMj6tHg1mivDs7jyrvn54_-X8or769PHy_O1VbTklqVYgFTW07xsxqLajXTsYSSQ1QlBoesygw5xyzAfOrcJGMmEH3nEKpuVMUHZWXW66vTejXoI7mHCrvXH6Z8GHvTYhOTuBll1HlMSmF4o3VNpOCSa6PLpXg2mgzVovN60l-JsVYtIHFy1Mk5nBr1ETKbKLDZNlLN2gNvgYAwz3ownWJQp61CUKukSh1HIUMunFnf7aHaC_p_zyPgNebwDIGzs6CDravE2bzQtgU_6S-7_-m7_odnJz8fob3EIc_Rrm7IUmOlKN9ecSxpJFwjGmnFH2A81R3s4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1765114372</pqid></control><display><type>article</type><title>Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients</title><source>BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS</source><source>ScienceDirect®</source><creator>Qiu, Yuan-wang ; Huang, Li-hua ; Yang, Wen-long ; Wang, Zhen ; Zhang, Bo ; Li, Yi-guang ; Su, Ting-ting ; Zhou, Hong-yan ; Xu, Wei ; Wang, Xue-dong ; Dai, Ya-ping ; Gan, Jian-he</creator><creatorcontrib>Qiu, Yuan-wang ; Huang, Li-hua ; Yang, Wen-long ; Wang, Zhen ; Zhang, Bo ; Li, Yi-guang ; Su, Ting-ting ; Zhou, Hong-yan ; Xu, Wei ; Wang, Xue-dong ; Dai, Ya-ping ; Gan, Jian-he</creatorcontrib><description>Highlights • Hepatitis B surface antigen (HBsAg) levels at hepatitis B e antigen (HBeAg) seroconversion may be an effective predictor of virological relapse. • The variation in HBsAg levels can help guide the timing of cessation of entecavir treatment. • Off-treatment virological relapse rates after stopping entecavir treatment were assessed.</description><identifier>ISSN: 1201-9712</identifier><identifier>EISSN: 1878-3511</identifier><identifier>DOI: 10.1016/j.ijid.2015.10.019</identifier><identifier>PMID: 26523639</identifier><language>eng</language><publisher>Canada: Elsevier Ltd</publisher><subject>Adult ; Antiviral Agents - administration &amp; dosage ; Biomarkers - blood ; China - epidemiology ; Chronic hepatitis B ; Entecavir ; Female ; Guanine - analogs &amp; derivatives ; Guanine - therapeutic use ; Hepatitis B e Antigens - blood ; Hepatitis B surface antigen ; Hepatitis B Surface Antigens - blood ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - epidemiology ; Hepatitis B, Chronic - immunology ; Humans ; Infectious Disease ; Male ; Middle Aged ; Pulmonary/Respiratory ; Recurrence ; Relapse ; Seroconversion - drug effects ; Treatment Outcome ; Viral Load - immunology ; Withdrawal</subject><ispartof>International journal of infectious diseases, 2016-02, Vol.43 (C), p.43-48</ispartof><rights>2016</rights><rights>Copyright © 2016. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c521t-9e792a2dd46f98b2b8fa7172a662e4d03eb052505f55c90a736cf5b52ea853623</citedby><cites>FETCH-LOGICAL-c521t-9e792a2dd46f98b2b8fa7172a662e4d03eb052505f55c90a736cf5b52ea853623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1201971215002532$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3547,27923,27924,45779</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26523639$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Qiu, Yuan-wang</creatorcontrib><creatorcontrib>Huang, Li-hua</creatorcontrib><creatorcontrib>Yang, Wen-long</creatorcontrib><creatorcontrib>Wang, Zhen</creatorcontrib><creatorcontrib>Zhang, Bo</creatorcontrib><creatorcontrib>Li, Yi-guang</creatorcontrib><creatorcontrib>Su, Ting-ting</creatorcontrib><creatorcontrib>Zhou, Hong-yan</creatorcontrib><creatorcontrib>Xu, Wei</creatorcontrib><creatorcontrib>Wang, Xue-dong</creatorcontrib><creatorcontrib>Dai, Ya-ping</creatorcontrib><creatorcontrib>Gan, Jian-he</creatorcontrib><title>Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients</title><title>International journal of infectious diseases</title><addtitle>Int J Infect Dis</addtitle><description>Highlights • Hepatitis B surface antigen (HBsAg) levels at hepatitis B e antigen (HBeAg) seroconversion may be an effective predictor of virological relapse. • The variation in HBsAg levels can help guide the timing of cessation of entecavir treatment. • Off-treatment virological relapse rates after stopping entecavir treatment were assessed.</description><subject>Adult</subject><subject>Antiviral Agents - administration &amp; dosage</subject><subject>Biomarkers - blood</subject><subject>China - epidemiology</subject><subject>Chronic hepatitis B</subject><subject>Entecavir</subject><subject>Female</subject><subject>Guanine - analogs &amp; derivatives</subject><subject>Guanine - therapeutic use</subject><subject>Hepatitis B e Antigens - blood</subject><subject>Hepatitis B surface antigen</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - epidemiology</subject><subject>Hepatitis B, Chronic - immunology</subject><subject>Humans</subject><subject>Infectious Disease</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pulmonary/Respiratory</subject><subject>Recurrence</subject><subject>Relapse</subject><subject>Seroconversion - drug effects</subject><subject>Treatment Outcome</subject><subject>Viral Load - immunology</subject><subject>Withdrawal</subject><issn>1201-9712</issn><issn>1878-3511</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9Uk1v1TAQjBCIlsIf4IB85JKHP2I7lhASVEArVeIAnC3H2bw65MWp7TypP5D_hU1KQQhxsr07MyvvTFU9J3hHMBGvxp0bXb-jmPBc2GGiHlSnpJVtzTghD_M9t2olCT2pnsQ4YowbIdrH1QkVnDLB1Gn1_QIWk1xyEb1DcQ2DsYDMnNweZnSzltvgbEb4GZmErv9A_8ZFCN76-QghFtwSoHc2RXR0wU9-n_kTCjCZJWbOkCCgdA3IQoybsB8QzAmsyQSUAph0yG_k5n_Pqxcfc-0IqDQzMj6tHg1mivDs7jyrvn54_-X8or769PHy_O1VbTklqVYgFTW07xsxqLajXTsYSSQ1QlBoesygw5xyzAfOrcJGMmEH3nEKpuVMUHZWXW66vTejXoI7mHCrvXH6Z8GHvTYhOTuBll1HlMSmF4o3VNpOCSa6PLpXg2mgzVovN60l-JsVYtIHFy1Mk5nBr1ETKbKLDZNlLN2gNvgYAwz3ownWJQp61CUKukSh1HIUMunFnf7aHaC_p_zyPgNebwDIGzs6CDravE2bzQtgU_6S-7_-m7_odnJz8fob3EIc_Rrm7IUmOlKN9ecSxpJFwjGmnFH2A81R3s4</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Qiu, Yuan-wang</creator><creator>Huang, Li-hua</creator><creator>Yang, Wen-long</creator><creator>Wang, Zhen</creator><creator>Zhang, Bo</creator><creator>Li, Yi-guang</creator><creator>Su, Ting-ting</creator><creator>Zhou, Hong-yan</creator><creator>Xu, Wei</creator><creator>Wang, Xue-dong</creator><creator>Dai, Ya-ping</creator><creator>Gan, Jian-he</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20160201</creationdate><title>Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients</title><author>Qiu, Yuan-wang ; Huang, Li-hua ; Yang, Wen-long ; Wang, Zhen ; Zhang, Bo ; Li, Yi-guang ; Su, Ting-ting ; Zhou, Hong-yan ; Xu, Wei ; Wang, Xue-dong ; Dai, Ya-ping ; Gan, Jian-he</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c521t-9e792a2dd46f98b2b8fa7172a662e4d03eb052505f55c90a736cf5b52ea853623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Antiviral Agents - administration &amp; dosage</topic><topic>Biomarkers - blood</topic><topic>China - epidemiology</topic><topic>Chronic hepatitis B</topic><topic>Entecavir</topic><topic>Female</topic><topic>Guanine - analogs &amp; derivatives</topic><topic>Guanine - therapeutic use</topic><topic>Hepatitis B e Antigens - blood</topic><topic>Hepatitis B surface antigen</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - epidemiology</topic><topic>Hepatitis B, Chronic - immunology</topic><topic>Humans</topic><topic>Infectious Disease</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pulmonary/Respiratory</topic><topic>Recurrence</topic><topic>Relapse</topic><topic>Seroconversion - drug effects</topic><topic>Treatment Outcome</topic><topic>Viral Load - immunology</topic><topic>Withdrawal</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Qiu, Yuan-wang</creatorcontrib><creatorcontrib>Huang, Li-hua</creatorcontrib><creatorcontrib>Yang, Wen-long</creatorcontrib><creatorcontrib>Wang, Zhen</creatorcontrib><creatorcontrib>Zhang, Bo</creatorcontrib><creatorcontrib>Li, Yi-guang</creatorcontrib><creatorcontrib>Su, Ting-ting</creatorcontrib><creatorcontrib>Zhou, Hong-yan</creatorcontrib><creatorcontrib>Xu, Wei</creatorcontrib><creatorcontrib>Wang, Xue-dong</creatorcontrib><creatorcontrib>Dai, Ya-ping</creatorcontrib><creatorcontrib>Gan, Jian-he</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qiu, Yuan-wang</au><au>Huang, Li-hua</au><au>Yang, Wen-long</au><au>Wang, Zhen</au><au>Zhang, Bo</au><au>Li, Yi-guang</au><au>Su, Ting-ting</au><au>Zhou, Hong-yan</au><au>Xu, Wei</au><au>Wang, Xue-dong</au><au>Dai, Ya-ping</au><au>Gan, Jian-he</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients</atitle><jtitle>International journal of infectious diseases</jtitle><addtitle>Int J Infect Dis</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>43</volume><issue>C</issue><spage>43</spage><epage>48</epage><pages>43-48</pages><issn>1201-9712</issn><eissn>1878-3511</eissn><abstract>Highlights • Hepatitis B surface antigen (HBsAg) levels at hepatitis B e antigen (HBeAg) seroconversion may be an effective predictor of virological relapse. • The variation in HBsAg levels can help guide the timing of cessation of entecavir treatment. • Off-treatment virological relapse rates after stopping entecavir treatment were assessed.</abstract><cop>Canada</cop><pub>Elsevier Ltd</pub><pmid>26523639</pmid><doi>10.1016/j.ijid.2015.10.019</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1201-9712
ispartof International journal of infectious diseases, 2016-02, Vol.43 (C), p.43-48
issn 1201-9712
1878-3511
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_7bb1970ad695427cb9636bdd4d9fa4e8
source BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS; ScienceDirect®
subjects Adult
Antiviral Agents - administration & dosage
Biomarkers - blood
China - epidemiology
Chronic hepatitis B
Entecavir
Female
Guanine - analogs & derivatives
Guanine - therapeutic use
Hepatitis B e Antigens - blood
Hepatitis B surface antigen
Hepatitis B Surface Antigens - blood
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - epidemiology
Hepatitis B, Chronic - immunology
Humans
Infectious Disease
Male
Middle Aged
Pulmonary/Respiratory
Recurrence
Relapse
Seroconversion - drug effects
Treatment Outcome
Viral Load - immunology
Withdrawal
title Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T22%3A40%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatitis%20B%20surface%20antigen%20quantification%20at%20hepatitis%20B%20e%20antigen%20seroconversion%20predicts%20virological%20relapse%20after%20the%20cessation%20of%20entecavir%20treatment%20in%20hepatitis%20B%20e%20antigen-positive%20patients&rft.jtitle=International%20journal%20of%20infectious%20diseases&rft.au=Qiu,%20Yuan-wang&rft.date=2016-02-01&rft.volume=43&rft.issue=C&rft.spage=43&rft.epage=48&rft.pages=43-48&rft.issn=1201-9712&rft.eissn=1878-3511&rft_id=info:doi/10.1016/j.ijid.2015.10.019&rft_dat=%3Cproquest_doaj_%3E1765114372%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c521t-9e792a2dd46f98b2b8fa7172a662e4d03eb052505f55c90a736cf5b52ea853623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1765114372&rft_id=info:pmid/26523639&rfr_iscdi=true